NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch
Aurinia Pharmaceuticals recently entered into a settlement with Teva Pharmaceuticals resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin capsules, with Teva agreeing that Aurinia’s patents, expiring in December 2037, are valid, enforceable, and would be infringed by U.S. sales of its generic.
The agreement, which restricts Teva from launching its generic voclosporin in the U.S. before December 7, 2036 (subject to contingencies and FDA approval), materially...